Tumor regressions and benefit from the given PI3K therapy was reported for combining mTORC1 inhibitors with carboplatin and paclitaxel chemotherapy, buparlisib at 100 mg daily plus cetuximab, BYL719 associated with cetuximab and radiation, Alpelisib in combination with cisplatin-based CRT (where the three-year overall survival was 77.8%), and Axitinib, a potent inhibitor of vascular endothelial growth factor receptor [14,15,16,17,19]. Here, PIK3CB is linked to neoplasm.